In conclusion, the important clinical relevance of our results and the discovered mechanism is proven by the negative survival outcome of TN breast cancer patients over-expressing HMGA2 as well as WNT10B. Thus, inhibition of the Wnt10b/β-catenin/HMGA2 signalling axis in TNBC patients could open new opportunities for future therapies. This evidence concerns the gene HMGA2 and breast carcinoma.